Skip to main content

Table 1 Patient demographics

From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Baseline characteristic Number
Total enrolled 9
Median (range) age (years) at study enrollment 46 (29–65)
Subtype
 ER+/HER2+ 7
 ER–/HER2+ 2
Median ECOG performance status 0 (0–1)
Prior lines of chemotherapy in the metastatic setting, median (range) 3 (2–6)
Prior lines of endocrine therapies in the metastatic setting, median (range) 1 (1–3)
Prior number of anti-HER2 agents in the metastatic setting, median (range)a 3 (2–4)
  1. negative, + positive, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, T-DM1 ado-trastuzumab emtansine
  2. aIncluding prior pertuzumab in 9/9 patients and T-DM1 in 8/9 patients